RxDoctor Payments Data

Jane Anderson, MD

Family Medicine · Janesville, WINPI 1942220140

Payments from drug & device makers

$568in general payments, 2019–2025

Across 16 payments — averaging $35.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$197
  • Dexcom, Inc.$125
  • Novo Nordisk$125
  • Merck$43
  • Pfizer$43
  • Exact Sciences$22
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$568100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK6$197
Dexcom, Inc.1$125
Novo Nordisk1$125
Merck3$43
Pfizer3$43
Exact Sciences1$22
Amarin Pharma, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$568 in reported general payments places this provider in the 80th percentile of 1,482 family medicine providers in Wisconsin.

See all family medicine providers in Wisconsin

Medicare billing

Part B allowed, 2024
$86,085
Medicare patients
275
Services billed
1,111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$111,487
OzempicSemaglutide85$92,851
JardianceEmpagliflozin45$37,836
TrulicityDulaglutide18$23,865
XareltoRivaroxaban52$23,724
Lantus SolostarInsulin Glargine,hum.Rec.Anlog95$14,471
Incruse ElliptaUmeclidinium Bromide18$7,364
Combivent RespimatIpratropium/Albuterol Sulfate13$5,940
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$5,861
Levothyroxine Sodium416$4,627
Omeprazole366$4,093
Atorvastatin Calcium432$4,058
Gabapentin185$3,429
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog11$3,298
Humalog Kwikpen U-100Insulin Lispro17$2,980

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$43$113,912112 claims
Novo NordiskOzempic$125$92,85185 claims
GSKIncruse Ellipta$197$7,36418 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,482 family medicine providers in Wisconsin.

Other family medicine in Janesville

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →